

Annual General Meeting of Siemens Healthineers AG

Munich, 15.2.2022

- Questions of DWS in the context of the virtual Annual General Meeting-

Dear Professor Thomas

Dear Dr. Montag,

Dear members of the Supervisory Board and the Management Board,

Please find our questions for your virtual Annual General Meeting 2022 below, where needed we added further explanations. We would like to thank you in advance for your response and would like to kindly ask you to provide us with the respective answers also in written form. We will publish these questions on our website until the day of your Annual General Meeting.

Regarding the past fiscal year:

Siemens Healthineers continued to demonstrate impressive business development in the second year of the corona pandemic: Record sales and earnings, a share price performance that clearly outperforms the DAX and, with the completed acquisition of Varian, a new basis for further growth. Siemens Healthineers is entering a new, exciting phase, strengthened operationally and strategically aligned with the "New Ambition". We would like to thank all employees, the Management Board and the Supervisory Board for their commitment, which has made these outstanding achievements possible, and we wish you all further success!

1. What focus topics have you identified for the New Ambition-phase up to 2025?
2. What is the holistic nature of this strategy?
3. Following up on a question we asked last year, can you already assess the impact of the pandemic on the health system and the demand of hospitals for expensive medical equipment, and what price developments are you observing?

On Corporate Governance: Supervisory Board - Independence, Overboarding and Discharge

We regard the economic strength of the company as an opportunity to also further

develop the corporate governance at Siemens Healthineers. We understand that Siemens AG, as the main shareholder, is prominently represented on the Supervisory Board and, with Professor Thomas, provides the Chairman of the Board. We also welcome the transfer of the chairmanship of the Audit Committee to Dr Helmes, but she is the only independent member of the Audit Committee besides Professor Thomas and Mr Hoffmann.

4. When and how will the composition of the Audit Committee, as well as the committees responsible for remuneration and succession planning, change so that a majority independent membership is achieved?

As DWS, we have already limited the number of mandates to a maximum of five for non-executive members of the Supervisory Board for several years, whereby we count the positions in the Chair of the Supervisory Board and Audit Committee twice. In addition to the audit committee of Siemens Healthineers, Dr Helmes also chairs this committee at Heineken, and is also a member of the supervisory board at ProSieben.Sat1Media SE and at British American Tobacco. Thus, she assumes a total of six mandates and is in our view overboarded.

5. How do you assess the overboarding situation of Dr Helmes resulting from her taking over the chairmanship of the Audit Committee?
6. Is a reduction of her mandates to be expected over the next twelve months?

As announced last year, we will vote against the discharge of the Supervisory Board because the majority of the committees is still not independent. We emphasize here, that this is not related to business performance.

7. What considerations are already being made today with regards to the nine out of ten mandates expiring at next year's annual general meeting?
8. Will you introduce a regular limit of term for supervisory board members at the next Annual General Meeting and make it public?
9. Why do you, as Siemens Healthineers, come to a different assessment of Ms. von Siemens' independence than your majority shareholder, Siemens AG, which considers Ms. von Siemens to be an independent member of the Supervisory

Board of Siemens AG, notwithstanding her role as representative of the largest single shareholder, the Siemens family?

On succession planning - diversity:

10. Can we assume that in the succession planning for the 2023 Annual General Meeting diversity will also play a greater role than in the past and that you will increase the proportion of female Supervisory Board members accordingly?
11. Which committee is responsible for succession planning?

On the election of the auditor:

Once again, we will not be able to approve the election of the auditor for transparency reasons. The invitation documents do not indicate how long the responsible auditor, Mr Siegfried Keller, has been auditing the financial statements of Siemens Healthineers.

12. Why did you not publish this information?

On the capital measures:

As last year, we will not be able to approve the capital measures proposed today. The proposed capital increase of 50% exceeds our limit of 40% of the share capital. Moreover, the exclusion of subscription rights is neither individually limited to the proposed capital nor complete and cumulative to 10% of the share capital. Furthermore, the proposed term of five years exceeds our limit of three years.

13. What do you intend to use these capital authorizations for?
14. Should we shareholders prepare for further, inorganic growth impulses of a comparable magnitude as with Varian?

On today's Annual General Meeting:

Once again, the shareholders only have the opportunity to follow answers to questions submitted to you in advance. You have once again excluded the possibility of legitimate further questions - despite the last comprehensive legal certainty.

15. Why?

16. Why do you not provide us with the answers in written form?

17. How many questions did you receive for today's Annual General Meeting?

We would like to thank you for answering these questions at the Annual General Meeting and expressly agree to our name being mentioned publicly in the context of the answer.